Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells

BMC Cancer

Cornel J Phillip³  Christopher K Giardina³  Birdal Bilir³  David J Cutler²  Yu-Heng Lai⁵  Omer Kucuk¹  Carlos S Moreno⁴ 

[1] Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

[2] Department of Human Genetics, Emory University, Atlanta, GA, USA

[3] Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

[4] Winship Cancer Institute, Emory University, Atlanta, GA, USA

[5] Graduate Program in Genetics and Molecular Biology, Emory University, Atlanta, GA, USA

关键词: Apoptosis;    Epigenetics;    Natural compounds;    Soy;    Prostate cancer;   

Others  :  1080462
DOI  :  10.1186/1471-2407-12-145

 received in 2011-08-10, accepted in 2012-03-23,  发布年份 2012

【 授权许可】

   
2012 Phillip et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010, 28(5):511-515.
• [2]Delmonte P, Perry J, Rader JI: Determination of isoflavones in dietary supplements containing soy, Red Clover and kudzu: extraction followed by basic or acid hydrolysis. J Chromatogr A 2006, 1107(1–2):59-69.
• [3]Sasamura H, Takahashi A, Yuan J, Kitamura H, Masumori N, Miyao N, Itoh N, Tsukamoto T: Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Urology 2004, 64(2):389-393.
• [4]Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK: Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999, 129(9):1628-1635.
• [5]Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, Sarkar FH: Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004, 3(10):1271-1279.
• [6]Singh AV, Franke AA, Blackburn GL, Zhou JR: Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 2006, 66(3):1851-1858.
• [7]Jagadeesh S, Kyo S, Banerjee PP: Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res 2006, 66(4):2107-2115.
• [8]Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005, 65(15):6934-6942.
• [9]Ye F, Wu J, Dunn T, Yi J, Tong X, Zhang D: Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett 2004, 211(1):39-46.
• [10]Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH: Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 2004, 28(4):e90-e95.
• [11]Wang Y, Raffoul JJ, Che M, Doerge DR, Joiner MC, Kucuk O, Sarkar FH, Hillman GG: Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 2006, 166(1 Pt 1):73-80.
• [12]Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR, Abrams J, Cher ML, Sarkar FH: Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004, 6(4):354-363.
• [13]Li Y, Sarkar FH: Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 2002, 186(2):157-164.
• [14]Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ: Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci 2003, 94(2):215-220.
• [15]Wei H, Saladi R, Lu Y, Wang Y, Palep SR, Moore J, Phelps R, Shyong E, Lebwohl MG: Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 2003, 133(11 Suppl 1):3811S-3819S.
• [16]Thigpen JE, Locklear J, Haseman JK, Saunders H, Grant MF, Forsythe DB: Effects of the dietary phytoestrogens daidzein and genistein on the incidence of vulvar carcinomas in 129/J mice. Cancer Detect Prev 2001, 25(6):527-532.
• [17]Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS: Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2005, 11(19 Pt 1):7033-7041.
• [18]Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R: Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 2008, 123(3):552-560.
• [19]Majid S, Dar AA, Ahmad AE, Hirata H, Kawakami K, Shahryari V, Saini S, Tanaka Y, Dahiya AV, Khatri G, Dahiya R: BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009, 30(4):662-670.
• [20]Majid S, Dar AA, Shahryari V, Hirata H, Ahmad A, Saini S, Tanaka Y, Dahiya AV, Dahiya R: Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 2010, 116(1):66-76.
• [21]Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007, 25(29):4603-4609.
• [22]Barnes S, Peterson TG, Coward L: Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem Suppl 1995, 22:181-187.
• [23]Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD: Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate 2009, 69(7):719-726.
• [24]Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64(6):1975-1986.
• [25]Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005, 65(10):4218-4227.
• [26]Guo L, Zhong D, Lau S, Liu X, Dong XY, Sun X, Yang VW, Vertino PM, Moreno CS, Varma V, Dong JT, Zhou W: Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res 2008, 6(9):1421-1430.
• [27]Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH, Zi X: The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010, 9:162. BioMed Central Full Text
• [28]Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011, 226(9):2378-2390.
• [29]Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW: Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 2008, 25(6):601-610.
• [30]McCabe CD, Spyropoulos DD, Martin D, Moreno CS: Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008, 68(6):1988-1996.
• [31]Li LC, Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11):1427-1431.
• [32]Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, Leamon JH, Johnson K, Milgrew MJ, Edwards M, Hoon J, Simons JF, Marran D, Myers JW, Davidson JF, Branting A, Nobile JR, Puc BP, Light D, Clark TA, Huber M, Branciforte JT, Stoner IB, Cawley SE, Lyons M, Fu Y, Homer N, Sedova M, Miao X, Reed B, Sabina J, Feierstein E, Schorn M, Alanjary M, Dimalanta E, Dressman D, Kasinskas R, Sokolsky T, Fidanza JA, Namsaraev E, McKernan KJ, Williams A, Roth GT, Bustillo J: An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475(7356):348-352.
• [33]Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98(9):5116-5121.
• [34]Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D: A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004, 10(24):8472-8478.
• [35]Singal R, Ferdinand L, Reis IM, Schlesselman JJ: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 2004, 12(3):631-637.
• [36]Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, Place RF, Pookot D, Dahiya R: Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008, 68(8):2736-2744.
• [37]Pavese JM, Farmer RL, Bergan RC: Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010, 29(3):465-482.
• [38]Santibanez JF, Navarro A, Martinez J: Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res 1997, 17(2A):1199-1204.
• [39]Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4(5):3. BioMed Central Full Text
• [40]Ingenuity[http://www.ingenuity.com/]. In.
• [41]Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH: Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006, 66(9):4816-4825.
• [42]Kumi-Diaka J, Merchant K, Haces A, Hormann V, Johnson M: Genistein-selenium combination induces growth arrest in prostate cancer cells. J Med Food 2010, 13(4):842-850.
• [43]Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A: The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003, 116(Pt 3):499-511.
• [44]Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103(8):1631-1643.
• [45]Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R: Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J 1999, 18(8):2196-2207.
• [46]Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA: Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene 2011, 30(2):167-177.